Study on Early Detection and Treatment of ER Positive HER2 Negative Breast Cancer Using Palbociclib, Fulvestrant, and Drug Combination for Patients with Molecular Relapse
Study on Early Detection and Treatment of ER Positive HER2 Negative Breast Cancer Using Palbociclib, Fulvestrant, and Drug Combination for Patients with Molecular Relapse
- Disease:Hormone receptor positive HER2 negative breast cancer
- Substances:AnastrozoleExemestane+4
France- Participants:18–64 years · 65+ years
- Substances:Anastrozole
- Sponsor:The Royal Marsden NHS Foundation Trust








